Previous 10 | Next 10 |
Inari Medical, Inc. (NARI) Q4 2020 Earnings Conference Call March 9, 2021 04:30 PM ET Company Participants Caroline Corner - Westwicke Partners, LLC William Hoffman - President and Chief Executive Officer Mitchell Hill - Chief Financial Officer Andrew Hykes - Chief Operating Officer Thomas Tu...
Inari Medical (NARI): Q4 GAAP EPS of $0.13 beats by $0.15.Revenue of $48.6M (+25.6% Y/Y) beats by $7.11M.Shares +8% AH.Press Release For further details see: Inari Medical EPS beats by $0.15, beats on revenue
IRVINE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial result...
Inari Medical (NASDAQ:NARI) is scheduled to announce Q4 earnings results on Tuesday, March 9th, after market close.The consensus EPS Estimate is $0.01 and the consensus Revenue Estimate is $41.49M.Over the last 3 months, EPS estimates have seen 1 upward revision and 2 downward. Revenue estima...
[[ABM]], [[AVAV]], [[HRB]], [[MDB]], [[NARI]], [[OSH]]For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Tuesday's close
Inari Medical, Inc. (NARI) has been losing momentum lately due to its lofty valuation and uncertain growth prospects, despite it making significant progress in product development and the treatment of clot in transit, a rare heart ailment. So, is the stock still a buy? Read more to find out. ...
IRVINE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today it will release...
In this episode of Industry Focus: Wildcard , host Dylan Lewis is joined by Motley Fool contributor Brian Feroldi to look at the results of GoodRx (NASDAQ: GDRX) , Inari (NASDAQ: NARI) , and Amwell (NYSE: AMWL) and check if they are still interesting enough f...
OptimizeRx (NASDAQ: OPRX) is a tiny small-cap that is still under $1 billion in valuation. But it probably won't stay there for long. Shares of this pharmaceutical marketing company have been soaring, running up nearly 450% over the last 12 months. And another fast-growing healthcar...
Healthcare lagged the broader market last year, but that can change this year. A cyclical upturn as the pandemic abates and pent-up demand can boost healthcare. Best positioned are industry groups within healthcare that can achieve secular growth beyond the cyclical rise. Biot...
News, Short Squeeze, Breakout and More Instantly...
IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its second quarter 2024...
Hagens Berman Encourages NARI Investors with Substantial Losses to Contact Firm Before July 12, 2024 Deadline San Francisco, California--(Newsfile Corp. - June 26, 2024) - Hagens Berman urges Inari Medical, Inc. (NASDAQ: NARI) investors who suffered substantial losses to submit your losses no...
2024-06-01 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...